3Cipriani, A, Geddes, JR, Furukawa, TA, Barbui, C. Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can J Psychiatry Rev r 2007 Sep; 52: 553–62.10.1177/070674370705200903
4Cipriani, A, Furukawa, TA, Salanti, G, Chaimani, A, Atkinson, LZ, Ogawa, Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 1357–66.10.1016/S0140-6736(17)32802-7
5Amick, HR, Gartlehner, G, Gaynes, BN, Forneris, C, Asher, GN, Morgan, LC, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ 2015; 351: h6019.10.1136/bmj.h6019
6Jonsson, U, Alaie, I, Parling, T, Arnberg, FK. Reporting of harms in randomized controlled trials of psychological interventions for mental and behavioral disorders: a review of current practice. Contemp Clin Trials 2014; 38: 1–8.10.1016/j.cct.2014.02.005
7Cleare, A, Pariante, CM, Young, AH, Anderson, IM, Christmas, D, Cowen, PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015; 29: 459–525.10.1177/0269881115581093
8Cuijpers, P, Cristea, IA. How to prove that your therapy is effective, even when it is not: a guideline. Epidemiol Psychiatr Sci 2016; 25: 428–35.10.1017/S2045796015000864
9National Institute for Health and Care Excellence. Depression in Adults: Treatment and Management. NICE, 2017.
10Cuijpers, P, Noma, H, Karyotaki, E, Vinkers, CH, Cipriani, A, Furukawa, TA. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry 2020; 19: 92–107.10.1002/wps.20701
11Strawbridge, R, Carter, B, Marwood, L, Bandelow, B, Tsapekos, D, Nikolova, VL, et al. Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Br J Psychiatry 2019; 214: 42–51.10.1192/bjp.2018.233
12McPherson, S, Hengartner, M. Long-term outcomes of trials in the National Institute for Health and Care Excellence depression guideline. Br J Psychiatry Open 2019; 5; e81. Available from: https://doi.org/10.1192/bjo.2019.65.
13Paykel, ES, Scott, J, Teasdale, JD, Johnson, AL, Garland, A, Moore, R, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 1999; 56: 829–35.10.1001/archpsyc.56.9.829
14Valenstein, M, Pfeiffer, PN, Brandfon, S, Walters, H, Ganoczy, D, Kim, HM, et al. Augmenting ongoing depression care with a mutual peer support intervention versus self-help materials alone: a randomized trial. Psychiatr Serv 2016; 67: 236–9.10.1176/appi.ps.201400454
15Hellerstein, DJ, Little, SA, Samstag, LW, Batchelder, S, Muran, JC, Fedak, M, et al. Adding group psychotherapy to medication treatment in dysthymia: a randomized prospective pilot study. J Psychother Pract Res 2001; 10: 93–103.
16Fonagy, P, Rost, F, Carlyle, J-A, Mcpherson, S, Thomas, R, Fearon, RMP, et al. Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock Adult Depression Study (TADS). World Psychiatry 2015 Oct; 14: 312–21.10.1002/wps.20267
17Wiles, N, Thomas, L, Abel, A, Ridgway, N, Turner, N, Campbell, J, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet 2013; 381: 375–84.10.1016/S0140-6736(12)61552-9
18Schramm, E, Schneider, D, Zobel, I, van Calker, D, Dykierek, P, Kech, S, et al. Efficacy of interpersonal psychotherapy plus pharmacotherapy in chronically depressed inpatients. J Affect Disord 2008; 109: 65–73.10.1016/j.jad.2007.10.013
19de Mello, MF, Myczcowisk, LM, Menezes, PR. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. J Psychother Pract Res 2001; 10: 117–23.
20Schramm, E, Zobel, I, Dykierek, P, Kech, S, Brakemeier, E-L, Külz, A, et al. Cognitive behavioral analysis system of psychotherapy versus interpersonal psychotherapy for early-onset chronic depression: a randomized pilot study. J Affect Disord 2011 Mar; 129: 109–16.10.1016/j.jad.2010.08.003
21Chiesa, A, Castagner, V, Andrisano, C, Serretti, A, Mandelli, L, Porcelli, S, et al. Mindfulness-based cognitive therapy vs. psycho-education for patients with major depression who did not achieve remission following antidepressant treatment. Psychiatry Res 2015; 226: 474–83.10.1016/j.psychres.2015.02.003
22Browne, G, Steiner, M, Roberts, J, Gafni, A, Byrne, C, Dunn, E, et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Disord 2002; 68: 317–30.10.1016/S0165-0327(01)00343-3
23Schramm, E, Zobel, I, Schoepf, D, Fangmeier, T, Schnell, K, Walter, H, et al. Cognitive behavioral analysis system of psychotherapy versus escitalopram in chronic major depression. Psychother Psychosom 2015; 84: 227–40.10.1159/000381957
24Andersson, G, Rozental, A, Shafran, R, Carlbring, P. Long-term effects of internet-supported cognitive behaviour therapy. Expert Rev Neurother 2018; 18: 21–8.10.1080/14737175.2018.1400381
25Marwood, L, Taylor, R, Goldsmith, K, Romeo, R, Holland, R, Pickles, A, et al. Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study). BMC Psychiatry 2017; 17: 231.10.1186/s12888-017-1393-0